- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00182455
Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP)
August 31, 2020 updated by: McMaster University
Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial.
SSRI's are considered first-line treatments for GSP, however many patients continue to have significant symptoms despite an adequate trial of an SSRI.
Topiramate, a drug, which targets the glutamate system in the brain, has been shown to improve symptoms of social phobia when used on its own and has also been used as an additive treatment in other anxiety disorders.
This study will test the efficacy of adding topiramate to a subject's current SSRI in cases of GSP which are considered to be treatment-resistant.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 1B7
- MacAnxiety Research Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Outpatient with primary DSM-IV GSP
- Completion of an adequate trial (14 wks) of open, flexible dose SSRI treatment (fluoxetine 80mg/day, paroxetine 60mg/day, fluvoxamine 300 mg/day, sertraline 200mg/day, citalopram 60mg/day, escitalopram 30mg/day)
- Non or partial response to SSRI treatment (CGI-S > 4, LSAS > 40)
Exclusion Criteria:
- Any other DSM-IV Axis I primary diagnosis
- Meeting DSM-IV criteria for body dysmorphic disorder, eating disorder or current alcohol/substance abuse
- A lifetime history of bipolar affective disorder
- A Hx of schizophrenia/psychotic disorders, delirium, dementia, or amnestic/other cognitive disorders
- Borderline/antisocial personality disorder
- A comorbid Axis II cluster A personality disorder
- Hx of > 3 adequate trials with an SSRI
- score of > 4 on MADRS q.10
- Current increased risk of suicide
- Prior use of or an allergy to topiramate
- Participation in any clinical trial 30 days prior to entering the study
- Unable to tolerate being free of or shows signs of withdrawal benzodiazepines for 4 weeks
- Hx of seizures, kidney stones or thyroid problems
- BMI < 20
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
25 - 400 mg/day x 12 weeks
|
Experimental: 1
Topiramate 25 - 400 mg/day x 12 weeks
|
25 - 400 mg/day x 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Global Impression - Improvement (CGI-I) ≤ 2
Time Frame: 12 weeks
|
12 weeks
|
Mean change in Liebowitz Social Anxiety Scale (LSAS)
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Montgomery Asberg Depression Rating Scale
Time Frame: 12 weeks
|
12 weeks
|
Beck Depression Inventory
Time Frame: 12 weeks
|
12 weeks
|
Social Phobia Scale
Time Frame: 12 weeks
|
12 weeks
|
Social Phobia Inventory
Time Frame: 12 weeks
|
12 weeks
|
Clinical Global Impression -Severity
Time Frame: 12 weeks
|
12 weeks
|
Quality of life and Employment Satisfaction Questionnaire Sheehan Disability Scale
Time Frame: 12 weeks
|
12 weeks
|
Beck Anxiety Inventory
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2004
Primary Completion (Actual)
December 1, 2018
Study Completion (Actual)
December 1, 2018
Study Registration Dates
First Submitted
September 14, 2005
First Submitted That Met QC Criteria
September 14, 2005
First Posted (Estimate)
September 16, 2005
Study Record Updates
Last Update Posted (Actual)
September 2, 2020
Last Update Submitted That Met QC Criteria
August 31, 2020
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 04-080
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Social Phobia
-
San Diego State UniversityNational Institute of Mental Health (NIMH)CompletedSocial Anxiety Disorder | Social PhobiaUnited States
-
Umeå UniversityUppsala UniversityCompleted
-
Umeå UniversityCompleted
-
Stanford UniversityNational Institute of Mental Health (NIMH)CompletedSocial PhobiaUnited States
-
University of MinnesotaAstraZenecaCompletedSocial PhobiaUnited States
-
Modum BadCompleted
-
VU University of AmsterdamCompletedSocial Anxiety Disorder | Social PhobiaNetherlands
-
Pherin Pharmaceuticals, Inc.CompletedSocial Anxiety Disorder | Social PhobiaUnited States
-
Umeå UniversityCompleted
Clinical Trials on Topiramate
-
Johnson & Johnson Taiwan LtdCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Supernus Pharmaceuticals, Inc.Completed
-
University of CopenhagenR W Johnson Pharmaceutical Research InstituteTerminated
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedObesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Adult-Onset
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedObesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Adult-Onset
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedMigraine | Headache | Common Migraine | Classic Migraine